DYN — Dyne Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.50bn
- $3.05bn
- 36
- 18
- 93
- 47
Annual cashflow statement for Dyne Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -14.9 | -59.4 | -149 | -168 | -236 |
| Depreciation | |||||
| Non-Cash Items | 1.35 | 7.12 | 19.4 | 18.1 | 19.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.41 | 5.11 | 9.26 | -5.38 | 26.3 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Cash from Operating Activities | -11.8 | -46.5 | -120 | -154 | -188 |
| Capital Expenditures | -1.65 | -1.16 | -3.62 | -3.07 | -0.729 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -44.5 | -134 | 90.3 | 84 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.65 | -45.7 | -138 | 87.2 | 83.3 |
| Financing Cash Flow Items | 0 | -0.45 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 20 | 381 | 158 | 37.4 | 54.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 6.51 | 289 | -99.6 | -29.1 | -50.5 |